Drug Trial Radar · NCT01185821
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Mar 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
185
Actual
Start
Aug 30, 2010
Primary completion
Oct 10, 2016
Study completion Oct 10, 2016
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 20, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 56 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg for approximately a further 3 years. It will provide data on long term safety, tolerability and efficacy of siponimod in the RRMS patient population
Conditions
- Relapsing Remitting Multiple Sclerosis
Interventions
BAF312Drug
BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study.Time frame: Baseline up to approximately 5 years
- Number of Participants With Cardiac Conduction Abnormalities During the Titration Phase of the Study (Without Washout)Time frame: Baseline Extension up to day 10
- Number of Participants With Cardiac Conduction-IVCD Abnormality During the Titration Phase of the Study (With Washout)Time frame: Baseline Extension up to day 10
- Number of Participants With Changes in Blood Pressure for Overall Extension Study. (Extension Analysis Set)Time frame: Baseline Extension up to approximately 5 years
- Number of Participants With Viral Infections of Interest Greater or Equal to 5% in Any Dose Group (Extension Set)Time frame: Baseline Extension up to approximately 5 years
- Number of Participants With Dermatologic Alterations - Basal Cell Carcinoma (Extension Set)Time frame: Baseline Extension up to approximately 5 years
Locations
46 sites in 12 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Pompano Beach, Florida
Novartis Investigative Site
Tallahassee, Florida
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Grand Rapids, Michigan
Novartis Investigative Site
Akron, Ohio
Novartis Investigative Site
Greenville, South Carolina
Novartis Investigative Site
Seattle, Washington
Novartis Investigative Site
Ottawa, Ontario, Canada
Novartis Investigative Site
Gatineau, Quebec, Canada
Novartis Investigative Site
Greenfield Park, Quebec, Canada
Novartis Investigative Site
Helsinki, Finland
Novartis Investigative Site
Tampere, Finland
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Ibbenbueren, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Debrecen, Hungary
Novartis Investigative Site
Veszprém, Hungary
Novartis Investigative Site
Montichiari, BS, Italy
Novartis Investigative Site
Chieti, CH, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Bergen, Norway
Novartis Investigative Site
Oslo, Norway
Novartis Investigative Site
Lodz, Poland
Novartis Investigative Site
Lublin, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Kazan', Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Seville, Andalusia, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Valencia, Valencia, Spain
Novartis Investigative Site
Basel, Switzerland
Novartis Investigative Site
Lugano, Switzerland
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.